KM
ANIK icon

Kalos Management’s Anika Therapeutics ANIK Stock Holding History

Kalos Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-9,018
Closed -$484K – 139
2016
Q2 		$484K Sell
9,018
-10,236
-53% -$482K 0.37% 82
2016
Q1 		$861K Buy
+19,254
New +$781K 0.72% 50
2015
Q4 		– Hold
0
– – – 59

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Kalos Management's ANIK Position: Q3 2016 in Review

Kalos Management sold out of Anika Therapeutics (ANIK) in Q3 2016, closing a stake of 9,018 shares — an estimated $484K sold.

Kalos Management first reported a position in ANIK in Q1 2016 and held it in 2 quarters. The position peaked at $861K in Q1 2016. 163 funds tracked by Wall St. Rank hold ANIK as of Q3 2016.

  • Kalos Management reported no remaining Anika Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Kalos Management sold 9,018 Anika Therapeutics shares in Q3 2016, an estimated $484K.
  • Kalos Management first reported a position in Anika Therapeutics in Q1 2016 and held it in 2 quarters.
  • Kalos Management's Anika Therapeutics position peaked at $861K in Q1 2016.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2016.

Based on Kalos Management's 13F filing for Q3 2016, filed 15 Nov 2016.